You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR VON WILLEBRAND FACTOR (RECOMBINANT)


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for von willebrand factor (recombinant)

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004357 ↗ Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed Ann & Robert H Lurie Children's Hospital of Chicago Phase 2 1997-09-01 Juvenile dermatomyositis (JDM) is a connective tissue disease that causes skin rash and weak muscles in children. The purpose of this study is to measure the absorption of oral prednisolone and intravenous (IV) methylprednisolone and to determine levels of disease activity indicators in the blood. These levels will be compared to see if there are patterns specific to active and less active JDM.
NCT00004357 ↗ Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed Northwestern University Phase 2 1997-09-01 Juvenile dermatomyositis (JDM) is a connective tissue disease that causes skin rash and weak muscles in children. The purpose of this study is to measure the absorption of oral prednisolone and intravenous (IV) methylprednisolone and to determine levels of disease activity indicators in the blood. These levels will be compared to see if there are patterns specific to active and less active JDM.
NCT00004360 ↗ Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed Northwestern University 1995-09-01 OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004360 ↗ Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-09-01 OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004667 ↗ Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease Completed University of North Carolina Phase 1 1993-10-01 OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease. II. Assess the safety of von Willebrand factor in these patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for von willebrand factor (recombinant)

Condition Name

Condition Name for von willebrand factor (recombinant)
Intervention Trials
Von Willebrand Disease 12
Hemophilia A 8
Von Willebrand Diseases 5
Liver Cirrhosis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for von willebrand factor (recombinant)
Intervention Trials
Von Willebrand Diseases 23
Hemophilia A 17
Hemorrhage 11
Blood Coagulation Disorders 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for von willebrand factor (recombinant)

Trials by Country

Trials by Country for von willebrand factor (recombinant)
Location Trials
United States 111
Germany 15
Spain 12
France 9
Austria 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for von willebrand factor (recombinant)
Location Trials
California 12
New York 9
Illinois 8
Pennsylvania 7
North Carolina 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for von willebrand factor (recombinant)

Clinical Trial Phase

Clinical Trial Phase for von willebrand factor (recombinant)
Clinical Trial Phase Trials
Phase 4 29
Phase 3 19
Phase 2/Phase 3 4
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for von willebrand factor (recombinant)
Clinical Trial Phase Trials
Completed 54
Unknown status 16
Recruiting 16
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for von willebrand factor (recombinant)

Sponsor Name

Sponsor Name for von willebrand factor (recombinant)
Sponsor Trials
CSL Behring 5
National Cancer Institute (NCI) 5
University of North Carolina 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for von willebrand factor (recombinant)
Sponsor Trials
Other 148
Industry 57
NIH 11
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.